Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. - Wikidata - wikimedia - TriplyDB

Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial.

Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial.

http://www.wikidata.org/entity/Q33881449

about

Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention: summary of key research and implications for policy and practice - biomedical prevention Antiviral therapy for genital herpes for prevention of HIV transmission Human Herpesviruses as Copathogens of HIV Infection, Their Role in HIV Transmission, and Disease Progression Infectious co-factors in HIV-1 transmission herpes simplex virus type-2 and HIV-1: new insights and interventions Herpes simplex virus type 2 and HIV disease progression: a systematic review of observational studies The Role of Sexually Transmitted Infections in HIV-1 Progression: A Comprehensive Review of the Literature Integrating prevention interventions for people living with HIV into care and treatment programs: a systematic review of the evidence.Development and application of modern agricultural biotechnology in Botswana: the potentials, opportunities and challenges Effects of valacyclovir on markers of disease progression in postpartum women co-infected with HIV-1 and herpes simplex virus-2 Infant safety during and after maternal valacyclovir therapy in conjunction with antiretroviral HIV-1 prophylaxis in a randomized clinical trial Setting the stage: current state of affairs and major challenges.Episodic therapy for genital herpes in sub-saharan Africa: a pooled analysis from three randomized controlled trials.Clinical reactivations of herpes simplex virus type 2 infection and human immunodeficiency virus disease progression markers.Could misreporting of condom use explain the observed association between injectable hormonal contraceptives and HIV acquisition risk?Variants in host viral replication cycle genes are associated with heterosexual HIV-1 acquisition in Africans Prevalence and risk factors associated with herpes simplex virus-2 infection in a contemporary cohort of HIV-infected persons in the United States Herpes simplex virus type 2, genital ulcers and HIV-1 disease progression in postpartum women.HSV-2 infection of dendritic cells amplifies a highly susceptible HIV-1 cell target.Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples.Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study.Can we reduce the spread of HIV infection by suppressing herpes simplex virus type 2 infection?Use of acyclovir for suppression of human immunodeficiency virus infection is not associated with genotypic evidence of herpes simplex virus type 2 resistance to acyclovir: analysis of specimens from three phase III trials.Short communication: a repeated simian human immunodeficiency virus reverse transcriptase/herpes simplex virus type 2 cochallenge macaque model for the evaluation of microbicides Can herpes simplex virus type 2 suppression slow HIV disease progression: a study protocol for the VALacyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trial Mortality in members of HIV-1 serodiscordant couples in Africa and implications for antiretroviral therapy initiation: results of analyses from a multicenter randomized trial.Comparative performance of the Uni-Gold™ HSV-2 Rapid: a point-of-care HSV-2 diagnostic test in unselected sera from a reference laboratory.Effect of genital herpes on cervicovaginal HIV shedding in women co-infected with HIV AND HSV-2 in Tanzania.Sensitivity and specificity of herpes simplex virus-2 serological assays among HIV-infected and uninfected urban Ugandans Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012.Quantitative and qualitative correlates of cervicovaginal herpes simplex virus type 2 shedding among HIV-infected women in the Women's Interagency HIV Study.The role of coinfections in HIV epidemic trajectory and positive prevention: a systematic review and meta-analysis Cervico-vaginal tissue ex vivo as a model to study early events in HIV-1 infection.Brief report: HIV-1 transmissions during asymptomatic infection: exploring the impact of changes in HIV-1 viral load due to coinfections.Time to refocus on HSV interventions for HIV prevention?Interventions to prevent sexually transmitted infections, including HIV infection.High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial Valacyclovir Decreases Plasma HIV-1 RNA in HSV-2 Seronegative Individuals: A Randomized Placebo-Controlled Crossover Trial.Association of recent HIV infection and in-utero HIV-1 transmission.

P2860

Q21144606-5B97ACDA-5563-4FEA-AC8A-BA5EC9A50FE5 Q21198769-2332D85A-440A-49A5-B36F-D827585FD219 Q24234315-AF855DE9-4132-465E-B772-CF0311984F00 Q26751304-082F590A-CCBB-49E1-A9D7-7F9FCA2D2328 Q26823594-FBFD6EEF-9DF0-4771-B04C-3CAD3DCAF0ED Q26861777-36E50852-0073-4CCF-A15E-A805888302DC Q26864344-4547E2DD-A4BE-4007-BA09-BFE178BA9C0F Q27313271-ECE480FB-D129-4E2F-B048-5E9BE4AD0046 Q28598433-AD98DFE5-BAC0-47F7-B4F2-0FB4DE462662 Q28728582-D187F106-F856-4969-922A-1039CED7B837 Q28730640-427F7249-8B64-4EF7-A9A7-11F19B925E4E Q30388160-6F3EFEB4-443B-4B84-9813-A2A8080328C9 Q31028568-4BA209B2-8D1C-4E98-9EC6-8F5E95BA413A Q33550768-AA20F297-0422-495D-BA6D-A96EEC0C64CE Q33552342-E2CEE411-CADB-4911-87F1-BA4D50A84ED3 Q33630030-4891C406-0F09-46D1-A080-DF9763D83E7A Q33813876-A806ACD6-4915-4174-BC4D-80C02678C8C0 Q33921326-F92FDE63-1E3B-4A5C-A142-D6650F3F2595 Q33954386-D5956E22-AE32-4F50-9492-CC9D79122C74 Q34030252-241C20A6-0B3E-4FB3-97BD-9BB28E94C59B Q34067511-A3709A7C-9576-4672-BD40-257AC3112BD3 Q34081339-F874BAD5-274E-4738-855F-67C8994E5E4A Q34175582-86CFB8B8-4D94-428B-B50D-0FFE7B286691 Q34190321-A8E8C475-7AD9-4458-ABF2-80CBB06E50B8 Q34399737-2947AB87-8AEB-43C0-9D29-1F17EC456752 Q34408313-14FCB4DC-5006-4731-8C52-75DD7892FAE2 Q34468239-2ECC0E16-63E8-4CB2-AB57-2C48750C0BBE Q34615201-281659A2-9232-498D-9950-C55FB8113BA7 Q34630266-8B492D83-2C16-4D72-BEB9-ED29036650D1 Q34670442-335E0024-38C5-4FCC-8B68-722518A3B802 Q34995329-B902DF03-04D2-4A82-BF0A-4BD48BC55462 Q35070290-7E0D9082-2146-4C50-B0B0-892E30DBB028 Q35149893-C328DCE2-09FC-4579-81A1-A674F90CBCD4 Q35252587-23CF8910-CB0A-4CED-A8DF-85419629FE5A Q35288465-B456C226-ADC6-4502-BCEB-E103EF3CFA03 Q35532849-56275230-29C1-4C3D-9EC6-430A5F4902A9 Q35542152-11C9401A-D73E-4768-B957-C7F096106469 Q35639207-8CFE1637-D7AC-4F6F-ABC1-BABA5EE65B33 Q35661728-8A7F96CC-E60B-46C8-B3DD-6BB27C512836 Q35688075-D19E07E9-34F6-4A93-A773-E4E218DEE7F2

P2860

Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial.

http://www.wikidata.org/entity/Q33881449

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Daily acyclovir for HIV-1 dise ...... ised placebo-controlled trial.

@ast

Daily acyclovir for HIV-1 dise ...... ised placebo-controlled trial.

@en

type

label

Daily acyclovir for HIV-1 dise ...... ised placebo-controlled trial.

@ast

Daily acyclovir for HIV-1 dise ...... ised placebo-controlled trial.

@en

prefLabel

Daily acyclovir for HIV-1 dise ...... ised placebo-controlled trial.

@ast

Daily acyclovir for HIV-1 dise ...... ised placebo-controlled trial.

@en

P1433

Q33881449-FD537C0D-F4EC-4570-9A2F-178BBE7C417D

P1476

Q33881449-C4DCF34C-D71C-4C7C-ACEF-033D2303765A

P2093

Q33881449-0F1065D3-C640-43D5-8F8A-752FE811F722

Q33881449-179B52A5-CF3F-427A-BDCE-F3DB4ACB25B1

Q33881449-1899078C-4AB4-4BA8-A156-80574291AB8D

Q33881449-20832DF8-1F6B-4D14-A96E-1069E8E40E98

Q33881449-2E0911E0-27E8-47EE-80F5-64BEECFA4E64

Q33881449-360817A6-00EE-48FC-A075-C32DC714F55A

Q33881449-3C781543-8417-4348-8D85-58C7F5BB515E

Q33881449-41504C3A-43A3-4960-A277-FD665164ABA9

Q33881449-484C76AE-F7F2-4EFC-8567-13B2DF1101B5

Q33881449-4F65679D-1A2B-447D-A2A4-D6F7E3682B51

P2860

Q33881449-06F319C6-7368-47E0-86FA-BD976251C345

Q33881449-08BE5AD6-3EA6-4649-A6EE-C5AAB2F3935B

Q33881449-0F42C569-F571-422F-83AD-8CEB2C60823F

Q33881449-180864BE-6BD4-4B6F-B602-FB83C792144D

Q33881449-1855D9A7-3FD5-4E9B-B11C-C3DF67D8864A

Q33881449-20EAEB34-64A9-4B14-A530-CE23925FE00E

Q33881449-40E4BD2E-F0CD-461E-9EE7-151FEF863FF3

Q33881449-43A562BC-A512-4A9E-A46E-D381AAD01C8C

Q33881449-45613A01-2E15-4F40-9143-282CE0ECA7B0

Q33881449-489AC817-CA2C-442D-8D3A-39C1F0CEDEC0

P304

Q33881449-36C97B6F-2562-43B5-9F17-42328A7DD959

P31

Q33881449-46DCF8CF-E888-4B2F-84B7-C943B13803BD

P356

Q33881449-78735162-28AB-4F36-A9F1-5DD2843F2E3C

P407

Q33881449-8BCCE2F9-C7CE-43CE-AA7B-14A28C8903ED

P433

Q33881449-E346B841-A832-4495-8103-EF2999DB4DE4

P478

Q33881449-1D0E89D4-BE0D-4716-B29E-CED919B8B299

P50

Q33881449-009F35EB-0457-4BC4-91F6-8C027A5D18CA

Q33881449-04467E29-831F-4083-94DB-7B2DD3A823F2

Q33881449-21358243-35C8-4127-AC86-0D5CC471AE84

Q33881449-3B85245A-048D-4597-A3E4-B2F631AAF8F1

Q33881449-4F971415-9FFA-4BC8-A674-860C17CAD5D1

Q33881449-558F56B2-0562-4E37-B5ED-DF83A43AE068

Q33881449-73CA03BE-7F33-477A-93CC-AD121B00535E

Q33881449-8F8FA6A1-C6F1-4F85-B2FD-D37ABA4B79A3

Q33881449-955B08F7-E058-48A4-A67A-444FB4BC55FE

Q33881449-9C99AEFB-E6FC-4CF6-B0C4-136C938E5A8A

P577

Q33881449-E9AA2A44-7272-4D53-A8ED-AE435210A7AA

P698

Q33881449-0638DD49-DC0A-4599-9C66-352A33BDA4E9

P921

Q33881449-2B96C038-E201-45C4-9C28-1AD2207130B0

P932

Q33881449-19C0404C-33FA-4B99-A219-E62F90E7DCB5

P356

S0140-6736(09)62038-9

P1433

P1476

Daily acyclovir for HIV-1 dise ...... ised placebo-controlled trial.

@en

P2093

Amalia S Magaret

http://www.w3.org/2001/XMLSchema#string

Andrew Mujugira

http://www.w3.org/2001/XMLSchema#string

Bellington Vwalika

http://www.w3.org/2001/XMLSchema#string

Carey Farquhar

http://www.w3.org/2001/XMLSchema#string

David Coetzee

http://www.w3.org/2001/XMLSchema#string

Edwin Were

http://www.w3.org/2001/XMLSchema#string

Glenda E Gray

http://www.w3.org/2001/XMLSchema#string

Grace John Stewart

http://www.w3.org/2001/XMLSchema#string

Guy de Bruyn

http://www.w3.org/2001/XMLSchema#string

Helen Rees

http://www.w3.org/2001/XMLSchema#string

P2860

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data.

Regional differences in prevalence of HIV-1 discordance in Africa and enrollment of HIV-1 discordant couples into an HIV-1 prevention trial.

Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study.

Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2.

Calculating the number needed to treat for trials where the outcome is time to an event

The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.

Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa

Epidemiology of herpes simplex virus type 2 infection in the developing world.

A randomized trial of multivitamin supplements and HIV disease progression and mortality.

P304

824-833

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0140-6736(09)62038-9

http://www.w3.org/2001/XMLSchema#string

P407

P433

9717

http://www.w3.org/2001/XMLSchema#string

P478

375

http://www.w3.org/2001/XMLSchema#string

P50

Partners in Prevention HSV/HIV Transmission Study Team

Kayitesi Kayitenkore

Elizabeth Bukusi

P577

2010-02-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20153888

http://www.w3.org/2001/XMLSchema#string

P921

P932

2877592

http://www.w3.org/2001/XMLSchema#string